Skip to main content

aTyr Pharma, Inc. (LIFE)

NASDAQ: LIFE · Delayed Price · USD
10.00
-0.31 (-3.01%)
Pre-market:Sep 20, 2021 6:55 AM EDT
10.31
0.05 (0.49%)
At close: Sep 17, 4:00 PM
Market Cap174.44M
Revenue (ttm)2.20M
Net Income (ttm)-29.07M
Shares Out16.13M
EPS (ttm)-2.30
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,568,916
Open9.84
Previous Close10.26
Day's Range9.31 - 10.54
52-Week Range2.93 - 12.97
Beta2.00
AnalystsBuy
Price Target19.40 (+88.2%)
Est. Earnings DateNov 11, 2021

About LIFE

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also...

IndustryBiotechnology
IPO DateMay 7, 2015
CEOSanjay Shukla
Employees40
Stock ExchangeNASDAQ
Ticker SymbolLIFE
Full Company Profile

Financial Performance

In 2020, aTyr Pharma's revenue was $10.46 million, an increase of 2,377.49% compared to the previous year's $422,000. Losses were -$16.22 million, -31.26% less than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for aTyr Pharma stock is "Buy." The 12-month stock price forecast is 19.40, which is an increase of 88.17% from the latest price.

Price Target
$19.40
(88.17% upside)
Analyst Consensus: Buy

News

What US Stocks Are The Largest Gainers In 2021?

The last two weeks haven't exactly been ideal for the major US indices. Since the end of August, the Dow Jones Industrial Average, the S&P 500, and the Nasdaq 100 have been down 1.54%, 0.93%, and 0.51%,...

Other symbols:AMCBTU
2 days ago - Benzinga

aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathw...

3 days ago - GlobeNewsWire

aTyr Pharma Announces Proposed Public Offering of Common Stock

SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel b...

4 days ago - GlobeNewsWire

aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.

5 days ago - Zacks Investment Research

LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soar on Study Results

Atyr Pharma (LIFE) stock is soaring higher on Tuesday after the company released positive data from a recent clinical trial. The post LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soa...

5 days ago - InvestorPlace

Why aTyr Pharma Shares Are Continuing To Surge Higher Today

aTyr Pharma Inc (NASDAQ: LIFE) is trading significantly higher Tuesday after multiple analyst firms maintained bullish ratings on the stock and raised their respective price targets following the compan...

5 days ago - Benzinga

Why Did Wainwright Beef Up ATyr Pharma's Price Target?

H.C. Wainwright increased the price target on ATyr Pharma (NASDAQ:LIFE) to $18 from $13, with the Buy rating unchanged, implying more than 120% upside. Today, the Company reported positive data from a p...

6 days ago - Benzinga

LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?

Today, some news of positive clinical trial results for one of aTry's leading drug candidates has sent LIFE stock surging. The post LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?

6 days ago - InvestorPlace

Why Are ATyr Pharma's Shares Trading Higher Today?

ATyr Pharma Inc (NASDAQ: LIFE) has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, a major form of interstitial lung ...

6 days ago - Benzinga

aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR19...

Trial met primary endpoint, ATYR1923 was safe and well-tolerated.

6 days ago - GlobeNewsWire

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial D...

Pangu's basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical proof-of-conce...

6 days ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in aTyr Pharma (LIFE) Stock?

Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -39.13% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

aTyr Pharma: Q2 Earnings Insights

Shares of aTyr Pharma (NASDAQ:LIFE) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 7.25% over the past year to ($0.64), which missed t...

1 month ago - Benzinga

aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021.

1 month ago - GlobeNewsWire

Pharmsynthez PJSC Secures RUB 800m With LDA Capital

LOS ANGELES--(BUSINESS WIRE)---- $LIFE #CapitalCommitment--Russian listed pharmaceutical manufacturer, Pharmsynthez PJSC (MOEX:LIFE), secures 800 million rubles from global alternative investor, LDA Cap...

2 months ago - Business Wire

aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

Event will feature Dr. Daniel Culver, Director of the Interstitial Lung Disease Program at the Cleveland Clinic.

2 months ago - GlobeNewsWire

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.

3 months ago - GlobeNewsWire

Atyr Pharma (LIFE) Reports Q1 Loss, Lags Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -50.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.

4 months ago - GlobeNewsWire

Analysts Estimate Atyr Pharma (LIFE) to Report a Decline in Earnings: What to Look Out for

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis

Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT

4 months ago - GlobeNewsWire

aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810

aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical develop...

5 months ago - Benzinga

aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virt...

Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer.

5 months ago - GlobeNewsWire

aTyr Pharma: Q4 Earnings Insights

Shares of aTyr Pharma (NASDAQ:LIFE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 69.48% over the past year to ($0.47), which beat the est...

5 months ago - Benzinga